Natus Medical Incorporated (NASDAQ:NTUS) CEO Jonathan Kennedy sold 8,676 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $32.65, for a total value of $283,271.40.
Shares of NASDAQ:NTUS traded up $0.20 during trading on Friday, reaching $32.65. 133,800 shares of the company traded hands, compared to its average volume of 256,912. Natus Medical Incorporated has a 52 week low of $22.25 and a 52 week high of $35.73. The business’s 50 day moving average price is $32.03. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.87 and a quick ratio of 1.36. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 22.99 and a beta of 0.71.
Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.02). The company had revenue of $123.46 million during the quarter, compared to analyst estimates of $124.75 million. Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.43%. The company’s quarterly revenue was down 5.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 EPS. As a group, sell-side analysts forecast that Natus Medical Incorporated will post 1.26 EPS for the current fiscal year.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Story: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.